Alzheimer’s Association:  Part the Cloud Translational Gene Targeting Challenge

If you are interested in this opportunity, please contact Carole King at carole.king@med.usc.edu.

• LOI due August 6, 2025
• Award up to $2,000,000 for phase two (including 10% indirects)
• Project period up to three years

This new grant mechanism aims to fill the gap in Alzheimer’s disease and related dementia clinical trials for advancing potential gene targeting (this could be anything that changes gene or gene produce expression) therapeutics forward by providing support for early phase studies (Phase 1 and Phase 2).

Symptomatic-only treatments are out of scope.

Each grant is limited to $1,000,000 (direct and indirect costs) for Phase 1 studies (early-stage testing) and $2,000,000 for Phase 2 studies (efficacy) over two or three years.